Ulcerative colitis is a chronic condition characterized by inflammation and ulcers in the colon. Research is ongoing to expand treatment options. A study published in the New England Journal of ...
An artificial intelligence-based endoscopic scoring system may better reflect symptoms and quality of life in ulcerative ...
AGA living guideline recommends patients start advanced therapies early in their disease course rather than gradual step-up treatment approach. “Since the first biologic treatment for ulcerative ...
A new cohort study from Northern Denmark finds that mild-onset Crohn's disease (CD) has worse 10-year probability of progression to moderate-severe disease, at 53%, than that of mild-onset ulcerative ...
LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe ...
Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Takeda presented promising data on its ulcerative colitis and Crohn’s disease drug Entyvio at the World Congress of Gastroenterology at ACG2017, Oct. 13 to Oct. 18 in Orlando, Fla. The data suggests ...
Ulcerative colitis can cause many unwanted symptoms in people. This can include stomach and digestive problems that can vary from person to person with the potential to impact your life. Ulcerative ...
Credit: Getty Images A 29-year-old man undergoes a total proctocolectomy with end-to-end ileostomy after 2 years of surveillance for ulcerative colitis. A 29-year-old White man presents in May 2023 ...
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback